# A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

> **NCT07294625** · EARLY_PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** LVIVO-TaVec200 product

## Key facts

- **NCT ID:** NCT07294625
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2027-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294625, "A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07294625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*